Ionis presents positive results from OASIS-HAE and OASISplus

Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing;...

Related Keywords

Spain , California , United States , San Diego , Valencia , Carabobo , Venezuela , Kenneth Newman , D Wade Walke , Hayley Soffer , Marc Riedl , European Academy Of Allergy , Linkedin , Exchange Commission , Angioedema Center , European Medicines Agency , Division Of Allergy Immunology , Otsuka Pharmaceutical Co Ltd , Drug Administration , Prnewswire Ionis Pharmaceuticals Inc , Nasdaq , University Of California , Ionis Pharmaceuticals , Ionis Pharmaceuticals Inc , European Academy , Clinical Immunology , Annual Congress , Brett Monia , Study Results , Open Label Extension , New Drug Application , Marketing Authorization Application , Hereditary Angioedema , Conjugated Antisense , Investor Contact , Wade Walke , Media Contact , Allergy Organ ,